Unfortunately we still don’t have RCT data comparing surgery vs SBRT in stage 1 NSCLC. This new study shows superior QoL and cost effectiveness (about 50% less expensive) with SBRT.

Two #radonc knowledge drops on #breastcancer post-mastectomy radiation therapy (PMRT) today First, my friend Simul Parikh made PMRT flowcharts: radiationeconomics.substack.com/p/beyond-b51-u… Second, ASTRO ASCO PMRT guideline publication (and a podcast!) ascopubs.org/doi/pdf/10.120… Biggest changes

When lung cancer is diagnosed early, survival rates are much higher. We must continue to advance therapies—but the greatest impact will likely come from earlier detection. American Lung Association

No RCT has yet proven SBRT = lobectomy in operable stage I NSCLC. Still, prospective data show SBRT preserves lung function better. Guidelines should acknowledge likely equipoise in survival outcomes, less financial toxicity and better lung function w/ SBRT.

Thank you Dr Gopal Bajaj for mentioning my Benign Radiotherapy Handbook during your ASTRO 2025 Presidential Symposium presentation “Translating Oncology Lessons Beyond Cancer.” #ASTRO2025 #benignradiotherapy

Could this be similar to how aspirin reduced recurrence risk by 50% in PIK3CA-mutated colorectal cancer in the ALASCCA trial? Not tested for in this study population, but we know this is one of the most common genetic aberrations in breast cancer.

This is how advocacy is done. Great job ASTRO 🙌🏻

It’s great to see the breakdown by cancer type. The data are especially interesting, in light of the controversy of SBRT for oligomet breast CA. Prostate cancer showed the longest FISST at 28 mo, followed by breast cancer at 23 mo, lung cancer at 17 mo…

🚨Attention Radiation Oncologists As functional radiotherapy grows in adoption for musculoskeletal conditions, it’s the real-world experience that unveils how nuanced and challenging these cases can be. The ASTRO three-part webinar series,, kicks off October 15 and is a

The anti-mRNA vaccine folks won’t like this. Excellent research and great news for oncology patients who need ICI treatment.

The economics of deploying autonomous, superintelligent robots in clinical care are staggering. At $499/month (Neo), the ROI curve is inevitable — and with more advanced robots on the way, their potential use cases are virtually limitless.